SE453089B - Imidazo-rifamycinderivat, forfarande for framstellning derav och farmaceutisk komposition - Google Patents

Imidazo-rifamycinderivat, forfarande for framstellning derav och farmaceutisk komposition

Info

Publication number: SE453089B
Authority: SE; Sweden
Prior art keywords: nothing; formula; hydrogen; imidazo; chemical bond
Prior art date: 1980-05-22

Application number

SE8103216A

Other languages

English (en)

Swedish (sv)

Other versions

SE8103216L (sv

Inventor

E Marchi

L Montecchi

Original Assignee

Alfa Farmaceutici Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-05-22

Filing date

1981-05-21

Publication date

1988-01-11

1981-05-21 Application filed by Alfa Farmaceutici Spa filed Critical Alfa Farmaceutici Spa

1981-11-23 Publication of SE8103216L publication Critical patent/SE8103216L/xx

1988-01-11 Publication of SE453089B publication Critical patent/SE453089B/sv

Links

238000000034 method Methods 0.000 title claims description 11
HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical class OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 title claims description 11
239000008194 pharmaceutical composition Substances 0.000 title description 3
150000001875 compounds Chemical class 0.000 claims description 69
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 25
239000000126 substance Substances 0.000 claims description 17
229910052739 hydrogen Inorganic materials 0.000 claims description 15
239000001257 hydrogen Substances 0.000 claims description 15
125000004432 carbon atom Chemical group C* 0.000 claims description 14
239000000203 mixture Substances 0.000 claims description 12
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 9
239000003960 organic solvent Substances 0.000 claims description 7
239000004480 active ingredient Substances 0.000 claims description 6
NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 claims description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 5
HJYYPODYNSCCOU-ZDHWWVNNSA-N Rifamycin SV Natural products COC1C=COC2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C)cc(O)c4c3C2=O HJYYPODYNSCCOU-ZDHWWVNNSA-N 0.000 claims description 5
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 5
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
229940109171 rifamycin sv Drugs 0.000 claims description 5
HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 claims description 4
125000001931 aliphatic group Chemical group 0.000 claims description 4
230000000844 anti-bacterial effect Effects 0.000 claims description 4
150000008282 halocarbons Chemical class 0.000 claims description 3
229910052740 iodine Inorganic materials 0.000 claims description 3
239000007800 oxidant agent Substances 0.000 claims description 3
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
229910052794 bromium Inorganic materials 0.000 claims description 2
239000003638 chemical reducing agent Substances 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
JEHCHYAKAXDFKV-UHFFFAOYSA-J lead tetraacetate Chemical compound CC(=O)O[Pb](OC(C)=O)(OC(C)=O)OC(C)=O JEHCHYAKAXDFKV-UHFFFAOYSA-J 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 claims description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
238000005904 alkaline hydrolysis reaction Methods 0.000 claims 1
150000002431 hydrogen Chemical group 0.000 claims 1
239000011630 iodine Substances 0.000 claims 1
239000007788 liquid Substances 0.000 claims 1
239000007787 solid Substances 0.000 claims 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
238000010521 absorption reaction Methods 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
238000000354 decomposition reaction Methods 0.000 description 11
238000002211 ultraviolet spectrum Methods 0.000 description 11
238000002329 infrared spectrum Methods 0.000 description 10
230000001580 bacterial effect Effects 0.000 description 9
239000002904 solvent Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
241000700159 Rattus Species 0.000 description 8
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000000968 intestinal effect Effects 0.000 description 6
239000011541 reaction mixture Substances 0.000 description 6
229910052938 sodium sulfate Inorganic materials 0.000 description 6
235000011152 sodium sulphate Nutrition 0.000 description 6
239000000243 solution Substances 0.000 description 6
238000005160 1H NMR spectroscopy Methods 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
238000001035 drying Methods 0.000 description 5
238000010828 elution Methods 0.000 description 5
238000001914 filtration Methods 0.000 description 5
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
125000000217 alkyl group Chemical group 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
210000003608 fece Anatomy 0.000 description 3
-1 for example Chemical group 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
230000002550 fecal effect Effects 0.000 description 2
239000012467 final product Substances 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
238000006722 reduction reaction Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
238000005406 washing Methods 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
FMBDGKGJYMSJKF-UHFFFAOYSA-N 2-phenylmethoxypyridine Chemical compound C=1C=CC=CC=1COC1=CC=CC=N1 FMBDGKGJYMSJKF-UHFFFAOYSA-N 0.000 description 1
RGDQRXPEZUNWHX-UHFFFAOYSA-N 3-methylpyridin-2-amine Chemical compound CC1=CC=CN=C1N RGDQRXPEZUNWHX-UHFFFAOYSA-N 0.000 description 1
ORLGLBZRQYOWNA-UHFFFAOYSA-N 4-methylpyridin-2-amine Chemical compound CC1=CC=NC(N)=C1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 1
CMBSSVKZOPZBKW-UHFFFAOYSA-N 5-methylpyridin-2-amine Chemical compound CC1=CC=C(N)N=C1 CMBSSVKZOPZBKW-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
229930189077 Rifamycin Natural products 0.000 description 1
BTVYFIMKUHNOBZ-ZDHWWVNNSA-N Rifamycin S Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC(=O)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C BTVYFIMKUHNOBZ-ZDHWWVNNSA-N 0.000 description 1
BTVYFIMKUHNOBZ-ODRIEIDWSA-N Rifamycin S Chemical compound O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-ODRIEIDWSA-N 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
229940126574 aminoglycoside antibiotic Drugs 0.000 description 1
239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
229950011175 aminopicoline Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
210000001557 animal structure Anatomy 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
OSILBMSORKFRTB-UHFFFAOYSA-N isoquinolin-1-amine Chemical compound C1=CC=C2C(N)=NC=CC2=C1 OSILBMSORKFRTB-UHFFFAOYSA-N 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000012071 phase Substances 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
239000013558 reference substance Substances 0.000 description 1
229960003292 rifamycin Drugs 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000036561 sun exposure Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

SE8103216A 1980-05-22 1981-05-21 Imidazo-rifamycinderivat, forfarande for framstellning derav och farmaceutisk komposition SE453089B (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT03429/80A IT1154655B (it)	1980-05-22	1980-05-22	Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica

Publications (2)

Publication Number	Publication Date
SE8103216L SE8103216L (sv)	1981-11-23
SE453089B true SE453089B (sv)	1988-01-11

Family

ID=11107198

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8103216A SE453089B (sv)	1980-05-22	1981-05-21	Imidazo-rifamycinderivat, forfarande for framstellning derav och farmaceutisk komposition

Country Status (25)

Country	Link
US (1)	US4341785A (fr)
JP (1)	JPS5711987A (fr)
AR (1)	AR226212A1 (fr)
AT (1)	AT373599B (fr)
AU (1)	AU537093B2 (fr)
BE (1)	BE888895A (fr)
CA (1)	CA1142518A (fr)
CH (1)	CH648037A5 (fr)
DE (1)	DE3120460A1 (fr)
DK (1)	DK157876C (fr)
EG (1)	EG14891A (fr)
ES (1)	ES502906A0 (fr)
FI (1)	FI69467C (fr)
FR (1)	FR2482967A1 (fr)
GB (1)	GB2079270B (fr)
GR (1)	GR75640B (fr)
IE (1)	IE51204B1 (fr)
IT (1)	IT1154655B (fr)
LU (1)	LU83376A1 (fr)
NL (1)	NL187022C (fr)
NO (1)	NO155622C (fr)
PH (2)	PH17207A (fr)
PT (1)	PT73064B (fr)
SE (1)	SE453089B (fr)
ZA (1)	ZA813430B (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1199374B (it) *	1984-05-15	1988-12-30	Alfa Farmaceutici Spa	Processo per la preparazione di pirido-imidazo-rifamicine
IT1264494B1 (it) *	1993-03-23	1996-09-24	Alfa Wassermann Spa	Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
US7048906B2 (en)	1995-05-17	2006-05-23	Cedars-Sinai Medical Center	Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) *	1999-08-11	2005-03-01	Cedars-Sinai Medical Center	Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5981522A (en) *	1995-09-01	1999-11-09	Kaneka Corporation	Treatment of disease caused by infection of Helicobacter
DE69829905T2 (de) *	1997-02-28	2006-03-09	Kaneka Corp.	Heilmittel für durch Helicobacter verursachte Krankheit
CA2465846A1 (fr) *	2001-11-21	2003-06-05	Activbiotics, Inc.	Agents therapeutiques cibles et leurs utilisations
WO2003051299A2 (fr) *	2001-12-13	2003-06-26	Activbiotics, Inc.	Rifamycines au sulfhydryle et utilisations de ces dernieres
EP1560566B1 (fr) *	2002-11-05	2012-04-11	Fadim S.r.l.	Delivrance continue et regulee de rifaximine
US7820652B2 (en) *	2003-09-24	2010-10-26	Activbiotics Pharma, Llc	Regimen for the administration of rifamycin-class antibiotics
US7902206B2 (en) *	2003-11-07	2011-03-08	Alfa Wassermann, S.P.A.	Polymorphic forms α, β and γ of rifaximin
US20080262024A1 (en) *	2003-11-07	2008-10-23	Giuseppe Claudio Viscomi	Rifaximin compositions and method of use
US7923553B2 (en) *	2003-11-07	2011-04-12	Alfa Wassermann, S.P.A.	Processes for the production of polymorphic forms of rifaximin
US7906542B2 (en) *	2004-11-04	2011-03-15	Alfa Wassermann, S.P.A.	Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) *	2003-11-07	2005-05-08	Alfa Wassermann Spa	Forme polimorfe di rifaximina, processi per ottenerle e
US7265107B2 (en) *	2004-03-10	2007-09-04	Cumbre Pharmaceuticals Inc.	Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes
US7256187B2 (en) *	2004-03-10	2007-08-14	Cumbre Pharmaceuticals Inc.	Rifamycin C-11 oxime derivatives effective against drug-resistant microbes
US7202246B2 (en) *	2004-06-09	2007-04-10	Cumbre Pharmaceuticals Inc.	Spiro-rifamycin derivatives targeting RNA polymerase
US20060210492A1 (en) *	2005-03-02	2006-09-21	Kodsi Robert E	Use of rifaximin for treatment and prevention of periodontal conditions
US8003118B2 (en) *	2005-03-02	2011-08-23	Kodsi Robert E	Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
US20060210483A1 (en) *	2005-03-02	2006-09-21	Kodsi Robert E	Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
EP1698630B1 (fr)	2005-03-03	2014-09-03	ALFA WASSERMANN S.p.A.	Nouvelles formes polymorphes du rifaximin, procédés pour leur préparation et leur utilisation en tant que médicaments
ITBO20050123A1 (it)	2005-03-07	2005-06-06	Alfa Wassermann Spa	Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
CA2618741C (fr)	2005-08-11	2014-03-25	Targanta Therapeutics Inc.	Rifamycines phosphonatees et utilisation pour la prevention des infections des os et des articulations
KR101398648B1 (ko)	2006-03-09	2014-06-27	샐릭스 파마슈티컬스 인코포레이티드	리팍시민 직장 기능장애 치료 제제
WO2008016708A2 (fr)	2006-08-02	2008-02-07	Salix Pharmaceuticals, Inc.	Compositions et procédés pour le traitement de la proctosigmoïdite de radiation
ITMI20061692A1 (it)	2006-09-05	2008-03-06	Alfa Wassermann Spa	Uso di polioli per ottenere forme polimorfe stabili di rifaximina
AU2007298733B2 (en) *	2006-09-22	2012-11-08	Cipla Limited	Rifaximin
US20080159987A1 (en) *	2007-01-03	2008-07-03	Leonard Weinstock	Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) *	2007-01-03	2008-07-03	Leonard Weinstock	Use of Rifaximin for the Treatment of Chronic Prostatitis
ITMI20071241A1 (it) *	2007-06-20	2008-12-21	Solmag S P A	Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
PT2011486E (pt)	2007-07-06	2012-08-24	Lupin Ltd	Composições farmacêuticas de rifaximina
JP5755878B2 (ja)	2007-07-06	2015-07-29	ルパンリミテッドＬｕｐｉｎＬｉｍｉｔｅｄ	リファキシミンの薬剤組成物
US7709634B2 (en) *	2007-09-20	2010-05-04	Apotex Pharmachem Inc.	Amorphous form of rifaximin and processes for its preparation
US8486956B2 (en)	2008-02-25	2013-07-16	Salix Pharmaceuticals, Ltd	Forms of rifaximin and uses thereof
EP2257557A4 (fr) *	2008-02-25	2011-06-29	Salix Pharmaceuticals Ltd	Formes de rifaximine et utilisations correspondantes
ES2727728T3 (es)	2008-02-26	2019-10-18	Salix Pharmaceuticals Ltd	Métodos para el tratamiento del síndrome del intestino irritable
US11779571B2 (en)	2008-02-26	2023-10-10	Salix Pharmaceuticals, Inc.	Methods for treating irritable bowel syndrome (IBS)
WO2009137672A1 (fr)	2008-05-07	2009-11-12	Salix Pharmaceuticals, Ltd.	Procédés de traitement de maladie intestinale par l’administration d’un nettoyant d’intestin et d’un antibiotique
US8524691B2 (en)	2008-08-13	2013-09-03	The Medicines Company	Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
PT2327407E (pt)	2008-09-26	2014-09-10	Aska Pharm Co Ltd	Agentes profiláticos e/ou terapêuticos para desordens gastrointestinais funcionais
US12285414B2 (en)	2008-10-02	2025-04-29	Salix Pharmaceuticals, Inc.	Methods of treating hepatic encephalopathy
DK3628319T3 (da)	2008-10-02	2024-03-04	Salix Pharmaceuticals Ltd	Behandling af hepatisk encefalopati ved anvendelse af rifaximin
KR20110107806A (ko)	2008-12-10	2011-10-04	시플라 리미티드	리팍시민 복합체
IT1397617B1 (it) *	2009-04-20	2013-01-18	Alfa Wassermann Spa	Nuovi derivati della rifamicina
RU2540513C2 (ru)	2009-06-02	2015-02-10	Саликс Фармасьютикалз, Лтд.	Способы лечения печеночной энцефалопатии
WO2011032085A1 (fr)	2009-09-13	2011-03-17	Salix Pharmaceuticals, Ltd.	Procédés pour le traitement du syndrome du côlon irritable
SG10201501054TA (en)	2009-10-27	2015-04-29	Lupin Ltd	Solid dispersion of rifaximin
AU2010320656B2 (en)	2009-11-23	2015-07-30	Cipla Limited	Topical foam composition
WO2011080691A1 (fr)	2009-12-28	2011-07-07	Silvio Massimo Lavagna	Procédés pour la production de rifaximine amorphe
AU2011218129A1 (en)	2010-02-18	2012-08-23	Board Of Regents Of The University Of Texas System	Methods for treating infection
IT1398550B1 (it)	2010-03-05	2013-03-01	Alfa Wassermann Spa	Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
US9211258B2 (en)	2010-03-10	2015-12-15	Lupin Limited	Rifaximin ready-to-use suspension
WO2012009387A1 (fr)	2010-07-12	2012-01-19	Salix Pharmaceuticals, Ltd	Formulations de rifaximine et utilisations correspondantes
WO2012035544A2 (fr)	2010-09-13	2012-03-22	Sequent Scientific Ltd.	Nouvelle forme polymorphe de rifaximine et son procédé de préparation
CA2825964A1 (fr)	2011-02-11	2012-08-16	Salix Pharmaceuticals, Ltd.	Formes de rifaximine et leurs utilisations
CA2834829A1 (fr)	2011-05-02	2012-11-08	Ranbaxy Laboratories Limited	Solvate de dimethylformamide rifaximine
ITMI20110890A1 (it)	2011-05-19	2012-11-20	A M S A Anonima Materie Sint & Affini S P A	Polimorfo di rifaximina e processo per la sua preparazione
ITBO20110461A1 (it)	2011-07-29	2013-01-30	Alfa Wassermann Spa	Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
RU2496475C2 (ru)	2011-10-26	2013-10-27	Александр Васильевич Иващенко	Фармацевтическая композиция и набор для лечения бактериальных инфекций
ES2986825T3 (es)	2011-11-02	2024-11-12	Salix Pharmaceuticals Inc	Rifaximina para la repetición de tratamiento del síndrome del intestino irritable con predominio de diarrea
AU2013212008A1 (en)	2012-01-25	2014-07-10	Alfa Wassermann S.P.A.	Rifaximin derivative and uses thereof
ITBO20120368A1 (it)	2012-07-06	2014-01-07	Alfa Wassermann Spa	Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
US9849090B2 (en)	2012-12-12	2017-12-26	Sun Pharmaceutical Industries Limited	Pharmaceutical compositions of rifaximin
US20160047819A1 (en)	2013-03-15	2016-02-18	Alfa Wassermann S.P.A.	Method for diagnosing vaginal infections
EP2968283A1 (fr)	2013-03-15	2016-01-20	ALFA WASSERMANN S.p.A.	Rifaximine destinée à être utilisée dans le traitement d'infections vaginales
KR102190173B1 (ko)	2013-04-12	2020-12-14	알파시그마 에스.피.에이.	Ｎｓａｉｄ 투여 및 관련 조성물, 방법 및 시스템
US9018225B1 (en)	2013-07-26	2015-04-28	Novel Laboratories	Rifaximin crystalline forms and methods of preparation thereof
ES2621557T3 (es)	2014-03-31	2017-07-04	Euticals S.P.A.	Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
CA2946101A1 (fr) *	2014-04-19	2015-10-22	Granules India Limited	Procede ameliore pour la preparation de derives de la rifamycine
CN106795192B (zh)	2014-05-04	2020-06-16	萨利克斯药品公司	Ibs微生物群及其用途
EP3143027B1 (fr)	2014-05-12	2019-07-10	Alfasigma S.p.A.	Nouvelle forme cristalline solvatée de rifaximine, production, compositions et utilisations de celle-ci
EP2982764A1 (fr)	2014-08-05	2016-02-10	ALFA WASSERMANN S.p.A.	Identification de bactérie vaginale
US9988398B2 (en)	2016-06-07	2018-06-05	Cadila Healthcare Limited	Crystalline form of rifaximin and process for its preparation
PT3518924T (pt)	2016-09-30	2022-10-27	Salix Pharmaceuticals Inc	Formas de dispersão sólidas de rifaximina
IT201700091912A1 (it) *	2017-08-08	2019-02-08	Biofer Spa	Nuove pirido-imidazo rifamicine
RU2020102511A (ru)	2017-06-26	2021-07-27	Биофер С.П.А.	Соединения пиридо-имидазо рифамицина в качестве антибактериального средства

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE273377C (fr) *
AT273377B (de) *	1967-03-01	1969-08-11	Lepetit Spa	Verfahren zur Herstellung von neuen Rifamycinen
AT344898B (de) *	1975-06-13	1978-08-10	Archifar Ind Chim Trentino	Verfahren zur herstellung neuer rifamycin-verbindungen
DK345977A (da) *	1976-09-30	1978-03-31	Archifar Ind Chim Trentino	G rifamycinforbindelser og fremgangsmaade til deres fremstillin
CH629212A5 (it) *	1976-10-18	1982-04-15	Erba Farmitalia	Procedimento per la preparazione di composti di rifamicina.
CH633014A5 (en) *	1978-06-09	1982-11-15	Erba Farmitalia	Rifamycin compounds

1980
- 1980-05-22 IT IT03429/80A patent/IT1154655B/it active Protection Beyond IP Right Term
1981
- 1981-05-11 NL NLAANVRAGE8102290,A patent/NL187022C/xx not_active IP Right Cessation
- 1981-05-11 US US06/262,123 patent/US4341785A/en not_active Expired - Lifetime
- 1981-05-18 AU AU70655/81A patent/AU537093B2/en not_active Expired
- 1981-05-19 AT AT0222781A patent/AT373599B/de not_active IP Right Cessation
- 1981-05-20 FR FR8110058A patent/FR2482967A1/fr active Granted
- 1981-05-20 PH PH25656A patent/PH17207A/en unknown
- 1981-05-20 PT PT73064A patent/PT73064B/pt unknown
- 1981-05-20 GR GR65010A patent/GR75640B/el unknown
- 1981-05-20 EG EG280/81A patent/EG14891A/xx active
- 1981-05-20 LU LU83376A patent/LU83376A1/fr unknown
- 1981-05-21 NO NO811731A patent/NO155622C/no unknown
- 1981-05-21 ZA ZA00813430A patent/ZA813430B/xx unknown
- 1981-05-21 FI FI811565A patent/FI69467C/fi not_active IP Right Cessation
- 1981-05-21 BE BE2/59169A patent/BE888895A/fr not_active IP Right Cessation
- 1981-05-21 ES ES502906A patent/ES502906A0/es active Granted
- 1981-05-21 SE SE8103216A patent/SE453089B/sv not_active IP Right Cessation
- 1981-05-21 DK DK224781A patent/DK157876C/da active
- 1981-05-21 CA CA000378015A patent/CA1142518A/fr not_active Expired
- 1981-05-21 IE IE1139/81A patent/IE51204B1/en not_active IP Right Cessation
- 1981-05-22 GB GB8115790A patent/GB2079270B/en not_active Expired
- 1981-05-22 DE DE19813120460 patent/DE3120460A1/de active Granted
- 1981-05-22 JP JP7787781A patent/JPS5711987A/ja active Granted
- 1981-05-22 CH CH3381/81A patent/CH648037A5/de not_active IP Right Cessation
- 1981-05-22 AR AR285424A patent/AR226212A1/es active
1982
- 1982-02-09 PH PH26842A patent/PH18704A/en unknown

Also Published As

Publication number	Publication date
GR75640B (fr)	1984-08-02
LU83376A1 (fr)	1981-09-11
AR226212A1 (es)	1982-06-15
IT1154655B (it)	1987-01-21
FI69467B (fi)	1985-10-31
GB2079270A (en)	1982-01-20
JPS6123192B2 (fr)	1986-06-04
EG14891A (en)	1985-12-31
IE811139L (en)	1981-11-22
ES8203388A1 (es)	1982-04-01
FR2482967B1 (fr)	1985-03-29
CA1142518A (fr)	1983-03-08
FI811565L (fi)	1981-11-23
PH18704A (en)	1985-09-05
CH648037A5 (de)	1985-02-28
ES502906A0 (es)	1982-04-01
JPS5711987A (en)	1982-01-21
PT73064A (en)	1981-06-01
ATA222781A (de)	1983-06-15
AU7065581A (en)	1981-11-26
NL187022B (nl)	1990-12-03
DE3120460C2 (fr)	1990-12-13
IT8003429A0 (it)	1980-05-22
DE3120460A1 (de)	1982-03-11
AU537093B2 (en)	1984-06-07
NO155622B (no)	1987-01-19
PH17207A (en)	1984-06-19
AT373599B (de)	1984-02-10
BE888895A (fr)	1981-09-16
FI69467C (fi)	1986-02-10
ZA813430B (en)	1982-06-30
DK157876C (da)	1990-07-30
NO155622C (no)	1987-04-29
FR2482967A1 (fr)	1981-11-27
DK157876B (da)	1990-02-26
NL187022C (nl)	1991-05-01
PT73064B (en)	1982-07-05
SE8103216L (sv)	1981-11-23
GB2079270B (en)	1984-01-18
NL8102290A (nl)	1981-12-16
IE51204B1 (en)	1986-10-29
US4341785A (en)	1982-07-27
DK224781A (da)	1981-11-23
NO811731L (no)	1981-11-23

Legal Events

Date

Code

Title

Description

1995-01-31

NAL

Patent in force

Ref document number: 8103216-1

Format of ref document f/p: F

2001-07-16

NUG

Patent has lapsed